Eptacog alfa biosimilar - AryoGen Pharmed

Drug Profile

Eptacog alfa biosimilar - AryoGen Pharmed

Alternative Names: AryoSeven

Latest Information Update: 03 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AryoGen Biopharma
  • Developer AryoGen Pharmed
  • Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Factor-VII-Deficiency; Haemophilia; Haemophilia A; Haemophilia B; Thrombasthenia

Most Recent Events

  • 21 Dec 2016 AryoGen Pharmed initiates enrolment in a phase III trial for Haemophilia A (In children, In adolescents, In adults) in Iran (IV) (IRCT2016120231193N1)
  • 25 Feb 2014 Launched prior to this date for Glanzmann’s Thrombasthenia in Iran (IV)
  • 25 Feb 2014 Launched prior to this date for Haemophilia B in Iran (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top